Corbus completes enrollment in CANYON-1 Phase 1b trial of CRB-913 for obesity; on track for summer 2026 data

Corbus Pharmaceuticals Holdings, Inc.

Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.
Trial is a 16-week, placebo-controlled, dose-ranging study (n=240) with 20, 40, and 60 mg QD cohorts; completion expected summer 2026.
Phase 1a data showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort, with no vomiting, constipation, or nausea reported.
Neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) were negative across all cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.